AMNEAL PHARMACEUTICALS, INC. Operating Income
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Operating Income of $129.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-06-30 was $129.77M, a 16.52% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-03-31 was $141.77M, a 41.28% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-12-31 was $112.03M, a 47.81% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-09-30 was $70.34M, a 20.79% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. operating income (loss) for fiscal 2025 was $394.10M, a 58.06% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. operating income (loss) for fiscal 2024 was $249.33M, a 21.99% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. operating income (loss) for fiscal 2023 was $204.37M.
- AMNEAL PHARMACEUTICALS, INC. operating income (loss) for fiscal 2022 was -$94.93M, a 162.16% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $129.77M 10-Q · filed 2026-08-06 | $271.54M 10-Q · filed 2026-08-06 | $383.57M derived: sum of 3 quarters · filed 2026-08-06 | $453.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $141.77M 10-Q · filed 2026-05-07 | $253.81M derived: sum of 2 quarters · filed 2026-05-07 | $324.15M derived: sum of 3 quarters · filed 2026-05-07 | $435.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $112.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $182.38M derived: sum of 2 quarters · filed 2026-02-27 | $293.75M derived: sum of 3 quarters · filed 2026-08-06 | $394.10M 10-K · filed 2026-02-27 |
| 2025-09-30 | $70.34M 10-Q · filed 2025-11-06 | $181.72M derived: sum of 2 quarters · filed 2026-08-06 | $282.06M 10-Q · filed 2025-11-06 | $357.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $111.37M 10-Q · filed 2026-08-06 | $211.72M 10-Q · filed 2026-08-06 | $287.51M derived: sum of 3 quarters · filed 2026-08-06 | $376.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $100.35M 10-Q · filed 2026-05-07 | $176.14M derived: sum of 2 quarters · filed 2026-05-07 | $264.95M derived: sum of 3 quarters · filed 2026-05-07 | $360.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $75.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $164.60M derived: sum of 2 quarters · filed 2026-02-27 | $260.07M derived: sum of 3 quarters · filed 2026-02-27 | $249.33M 10-K · filed 2026-02-27 |
| 2024-09-30 | $88.81M 10-Q · filed 2025-11-06 | $184.28M derived: sum of 2 quarters · filed 2025-11-06 | $173.53M 10-Q · filed 2025-11-06 | $187.73M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $95.47M 10-Q · filed 2025-08-07 | $84.72M 10-Q · filed 2025-08-07 | $98.92M derived: sum of 3 quarters · filed 2026-02-27 | $174.56M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$10.75M 10-Q · filed 2025-05-07 | $3.45M derived: sum of 2 quarters · filed 2026-02-27 | $79.09M derived: sum of 3 quarters · filed 2026-02-27 | $159.18M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $14.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $89.84M derived: sum of 2 quarters · filed 2026-02-27 | $169.93M derived: sum of 3 quarters · filed 2026-02-27 | $204.37M 10-K · filed 2026-02-27 |
| 2023-09-30 | $75.65M 10-Q · filed 2024-11-12 | $155.73M derived: sum of 2 quarters · filed 2024-11-12 | $190.18M 10-Q · filed 2024-11-12 | $226.21M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $80.08M 10-Q · filed 2024-08-09 | $114.53M 10-Q · filed 2024-08-09 | $150.56M derived: sum of 3 quarters · filed 2025-02-28 | $194.92M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $34.45M 10-Q · filed 2024-05-08 | $70.48M derived: sum of 2 quarters · filed 2025-02-28 | $114.83M derived: sum of 3 quarters · filed 2025-02-28 | -$83.78M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $36.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $80.39M derived: sum of 2 quarters · filed 2025-02-28 | -$118.23M derived: sum of 3 quarters · filed 2025-02-28 | -$94.93M 10-K · filed 2025-02-28 |
| 2022-09-30 | $44.35M 10-Q · filed 2023-11-09 | -$154.26M derived: sum of 2 quarters · filed 2023-11-09 | -$130.96M 10-Q · filed 2023-11-09 | -$119.78M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$198.62M 10-Q · filed 2023-08-08 | -$175.31M 10-Q · filed 2023-08-08 | -$164.14M derived: sum of 3 quarters · filed 2024-03-14 | -$135.62M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $23.30M 10-Q · filed 2023-05-09 | $34.48M derived: sum of 2 quarters · filed 2024-03-14 | $62.99M derived: sum of 3 quarters · filed 2024-03-14 | $130.11M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $11.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $39.69M derived: sum of 2 quarters · filed 2024-03-14 | $106.81M derived: sum of 3 quarters · filed 2024-03-14 | $152.72M 10-K · filed 2024-03-14 |
| 2021-09-30 | $28.52M 10-Q · filed 2022-11-07 | $95.63M derived: sum of 2 quarters · filed 2022-11-07 | $141.54M 10-Q · filed 2022-11-07 | $161.72M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $67.12M 10-Q · filed 2022-08-08 | $113.03M 10-Q · filed 2022-08-08 | $133.20M derived: sum of 3 quarters · filed 2023-03-03 | $135.64M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $45.91M 10-Q · filed 2022-05-06 | $66.08M derived: sum of 2 quarters · filed 2023-03-03 | $68.52M derived: sum of 3 quarters · filed 2023-03-03 | $79.27M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $20.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $22.61M derived: sum of 2 quarters · filed 2023-03-03 | $33.36M derived: sum of 3 quarters · filed 2023-03-03 | $91.16M 10-K · filed 2023-03-03 |
| 2020-09-30 | $2.44M 10-Q · filed 2021-11-08 | $13.19M derived: sum of 2 quarters · filed 2021-11-08 | $70.98M 10-Q · filed 2021-11-08 | $47.84M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $10.75M 10-Q · filed 2021-08-09 | $68.54M 10-Q · filed 2021-08-09 | $45.41M derived: sum of 3 quarters · filed 2022-03-01 | -$66.87M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $57.79M 10-Q · filed 2021-05-07 | $34.66M derived: sum of 2 quarters · filed 2022-03-01 | -$77.62M derived: sum of 3 quarters · filed 2022-03-01 | -$96.53M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$23.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$135.41M derived: sum of 2 quarters · filed 2022-03-01 | -$154.32M derived: sum of 3 quarters · filed 2022-03-01 | -$248.68M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$112.27M 10-Q · filed 2020-11-06 | -$131.19M derived: sum of 2 quarters · filed 2020-11-06 | -$225.55M 10-Q · filed 2020-11-06 | -$202.27M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$18.91M 10-Q · filed 2020-08-06 | -$113.27M 10-Q · filed 2020-08-06 | -$89.99M derived: sum of 3 quarters · filed 2021-03-01 | -$15.44M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$94.36M 10-Q · filed 2020-05-11 | -$71.08M derived: sum of 2 quarters · filed 2021-03-01 | $3.48M derived: sum of 3 quarters · filed 2021-03-01 | -$177.59M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $23.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $97.83M derived: sum of 2 quarters · filed 2021-03-01 | -$83.23M derived: sum of 3 quarters · filed 2021-03-01 | -$19.67M 10-K · filed 2021-03-01 |
| 2018-09-30 | $74.56M 10-Q · filed 2019-11-07 | -$106.51M derived: sum of 2 quarters · filed 2019-11-07 | -$42.95M 10-Q · filed 2019-11-07 | $36.07M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$181.06M 10-Q · filed 2019-08-05 | -$117.51M 10-Q · filed 2019-08-05 | -$38.49M derived: sum of 3 quarters · filed 2020-03-02 | $40.26M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $63.55M 10-Q · filed 2019-05-09 | $142.57M derived: sum of 2 quarters · filed 2020-03-02 | $221.33M derived: sum of 3 quarters · filed 2020-03-02 | $265.93M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $79.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $157.77M derived: sum of 2 quarters · filed 2020-03-02 | $202.38M derived: sum of 3 quarters · filed 2020-03-02 | $245.10M 10-K · filed 2020-03-02 |
| 2017-09-30 | $78.75M 10-Q · filed 2018-11-07 | $123.36M derived: sum of 2 quarters · filed 2018-11-07 | $166.08M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $44.60M 10-Q · filed 2018-08-09 | $87.33M 10-Q · filed 2018-08-09 | ||
| 2016-12-31 | $284.88M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |